This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Your saved search

Name of saved search:

Search terms:

Would you like email updates of new search results?

Email: (change)

Frequency:

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Published Erratum

. 2024 Jun 1;403(10442):2380.

doi: 10.1016/S0140-6736(24)01041-9.

No authors listed

Published Erratum

No authors listed. Lancet. 2024.

. 2024 Jun 1;403(10442):2380.

doi: 10.1016/S0140-6736(24)01041-9.

No abstract available

Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.
Kaul I, Sawchak S, Correll CU, Kakar R, Breier A, Zhu H, Miller AC, Paul SM, Brannan SK. Kaul I, et al. Lancet. 2024 Jan 13;403(10422):160-170. doi: 10.1016/S0140-6736(23)02190-6. Epub 2023 Dec 14. Lancet. 2024. PMID: 38104575 Clinical Trial.